JP2019528306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528306A5 JP2019528306A5 JP2019511610A JP2019511610A JP2019528306A5 JP 2019528306 A5 JP2019528306 A5 JP 2019528306A5 JP 2019511610 A JP2019511610 A JP 2019511610A JP 2019511610 A JP2019511610 A JP 2019511610A JP 2019528306 A5 JP2019528306 A5 JP 2019528306A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- insulin
- group
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 81
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 54
- 108010063919 Glucagon Receptors Proteins 0.000 claims description 53
- 102100040890 Glucagon receptor Human genes 0.000 claims description 53
- 150000001413 amino acids Chemical group 0.000 claims description 51
- 239000005557 antagonist Substances 0.000 claims description 50
- 239000000427 antigen Substances 0.000 claims description 49
- 108091007433 antigens Proteins 0.000 claims description 49
- 102000036639 antigens Human genes 0.000 claims description 49
- 239000012634 fragment Substances 0.000 claims description 49
- 239000003112 inhibitor Substances 0.000 claims description 48
- 206010022489 Insulin Resistance Diseases 0.000 claims description 47
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 47
- 102000051325 Glucagon Human genes 0.000 claims description 35
- 108060003199 Glucagon Proteins 0.000 claims description 35
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 35
- 229960004666 glucagon Drugs 0.000 claims description 35
- 229940125396 insulin Drugs 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 21
- 102000004877 Insulin Human genes 0.000 claims description 21
- 108090001061 Insulin Proteins 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- 239000008103 glucose Substances 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 208000011580 syndromic disease Diseases 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- -1 PIK2CA Proteins 0.000 claims description 16
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 12
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 12
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 12
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 12
- 150000002576 ketones Chemical class 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 8
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 6
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 6
- 102100038369 1-acyl-sn-glycerol-3-phosphate acyltransferase beta Human genes 0.000 claims description 6
- 102100033097 26S proteasome non-ATPase regulatory subunit 6 Human genes 0.000 claims description 6
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 6
- 102000017906 ADRA2A Human genes 0.000 claims description 6
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 6
- 201000005932 Alstrom Syndrome Diseases 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 6
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 claims description 6
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 claims description 6
- 102100021295 Bardet-Biedl syndrome 1 protein Human genes 0.000 claims description 6
- 229940123208 Biguanide Drugs 0.000 claims description 6
- 102100032378 Carboxypeptidase E Human genes 0.000 claims description 6
- 108010058255 Carboxypeptidase H Proteins 0.000 claims description 6
- 102100032230 Caveolae-associated protein 1 Human genes 0.000 claims description 6
- 102100032137 Cell death activator CIDE-3 Human genes 0.000 claims description 6
- 102100024395 DCC-interacting protein 13-alpha Human genes 0.000 claims description 6
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 claims description 6
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims description 6
- 201000005948 Donohue syndrome Diseases 0.000 claims description 6
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 6
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 108700031835 GRB10 Adaptor Proteins 0.000 claims description 6
- 102000053334 GRB10 Adaptor Human genes 0.000 claims description 6
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims description 6
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 claims description 6
- 101150090959 Grb10 gene Proteins 0.000 claims description 6
- 101000605571 Homo sapiens 1-acyl-sn-glycerol-3-phosphate acyltransferase beta Proteins 0.000 claims description 6
- 101001135306 Homo sapiens 26S proteasome non-ATPase regulatory subunit 6 Proteins 0.000 claims description 6
- 101000756842 Homo sapiens Alpha-2A adrenergic receptor Proteins 0.000 claims description 6
- 101000961044 Homo sapiens Atrial natriuretic peptide receptor 1 Proteins 0.000 claims description 6
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 claims description 6
- 101000894722 Homo sapiens Bardet-Biedl syndrome 1 protein Proteins 0.000 claims description 6
- 101000869049 Homo sapiens Caveolae-associated protein 1 Proteins 0.000 claims description 6
- 101000775558 Homo sapiens Cell death activator CIDE-3 Proteins 0.000 claims description 6
- 101001053277 Homo sapiens DCC-interacting protein 13-alpha Proteins 0.000 claims description 6
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 claims description 6
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 claims description 6
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 claims description 6
- 101001046596 Homo sapiens Krueppel-like factor 14 Proteins 0.000 claims description 6
- 101001063991 Homo sapiens Leptin Proteins 0.000 claims description 6
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 claims description 6
- 101001117010 Homo sapiens Pericentrin Proteins 0.000 claims description 6
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 claims description 6
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 claims description 6
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 claims description 6
- 101001069891 Homo sapiens RAS guanyl-releasing protein 1 Proteins 0.000 claims description 6
- 101000606537 Homo sapiens Receptor-type tyrosine-protein phosphatase delta Proteins 0.000 claims description 6
- 101000898985 Homo sapiens Seipin Proteins 0.000 claims description 6
- 101000891625 Homo sapiens TBC1 domain family member 4 Proteins 0.000 claims description 6
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 claims description 6
- 101000868883 Homo sapiens Transcription factor Sp6 Proteins 0.000 claims description 6
- 102100036721 Insulin receptor Human genes 0.000 claims description 6
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 claims description 6
- 102100022329 Krueppel-like factor 14 Human genes 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 6
- 229930064664 L-arginine Natural products 0.000 claims description 6
- 235000014852 L-arginine Nutrition 0.000 claims description 6
- 102000016267 Leptin Human genes 0.000 claims description 6
- 102100030874 Leptin Human genes 0.000 claims description 6
- 108010092277 Leptin Proteins 0.000 claims description 6
- 102100031775 Leptin receptor Human genes 0.000 claims description 6
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 6
- 102100023724 Melanocortin receptor 4 Human genes 0.000 claims description 6
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 102100024315 Pericentrin Human genes 0.000 claims description 6
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 6
- 102100026531 Prelamin-A/C Human genes 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 claims description 6
- 102100034220 RAS guanyl-releasing protein 1 Human genes 0.000 claims description 6
- 208000016140 Rabson-Mendenhall syndrome Diseases 0.000 claims description 6
- 102100039666 Receptor-type tyrosine-protein phosphatase delta Human genes 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 108091006277 SLC5A1 Proteins 0.000 claims description 6
- 102100021463 Seipin Human genes 0.000 claims description 6
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 claims description 6
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 6
- 229940100389 Sulfonylurea Drugs 0.000 claims description 6
- 102100040257 TBC1 domain family member 4 Human genes 0.000 claims description 6
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 6
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 6
- 102100035101 Transcription factor 7-like 2 Human genes 0.000 claims description 6
- 201000011032 Werner Syndrome Diseases 0.000 claims description 6
- 201000010272 acanthosis nigricans Diseases 0.000 claims description 6
- 229960002632 acarbose Drugs 0.000 claims description 6
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 6
- 239000000048 adrenergic agonist Substances 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 235000009697 arginine Nutrition 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 208000012696 congenital leptin deficiency Diseases 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims description 6
- 238000000249 far-infrared magnetic resonance spectroscopy Methods 0.000 claims description 6
- 201000010066 hyperandrogenism Diseases 0.000 claims description 6
- 208000010522 hyperproinsulinemia Diseases 0.000 claims description 6
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 6
- 229940039781 leptin Drugs 0.000 claims description 6
- 108010019813 leptin receptors Proteins 0.000 claims description 6
- 208000006132 lipodystrophy Diseases 0.000 claims description 6
- 229950004994 meglitinide Drugs 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 208000001022 morbid obesity Diseases 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 229960004586 rosiglitazone Drugs 0.000 claims description 6
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 6
- 229940035722 triiodothyronine Drugs 0.000 claims description 6
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical group CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 5
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 4
- 108091005466 amylin receptors Proteins 0.000 claims description 4
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 230000009229 glucose formation Effects 0.000 claims description 3
- 229940124035 Amylin receptor agonist Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 150000004283 biguanides Chemical group 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 2
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 claims 1
- 238000000034 method Methods 0.000 description 71
- 208000035475 disorder Diseases 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 101150089655 Ins2 gene Proteins 0.000 description 1
- 108091027076 Spiegelmer Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022122568A JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2024159035A JP2024178249A (ja) | 2016-08-30 | 2024-09-13 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381263P | 2016-08-30 | 2016-08-30 | |
| US62/381,263 | 2016-08-30 | ||
| US201662411032P | 2016-10-21 | 2016-10-21 | |
| US62/411,032 | 2016-10-21 | ||
| PCT/US2017/049137 WO2018044903A1 (en) | 2016-08-30 | 2017-08-29 | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122568A Division JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528306A JP2019528306A (ja) | 2019-10-10 |
| JP2019528306A5 true JP2019528306A5 (enExample) | 2020-10-08 |
| JP7173962B2 JP7173962B2 (ja) | 2022-11-16 |
Family
ID=59799505
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511610A Active JP7173962B2 (ja) | 2016-08-30 | 2017-08-29 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2022122568A Active JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2024159035A Pending JP2024178249A (ja) | 2016-08-30 | 2024-09-13 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122568A Active JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2024159035A Pending JP2024178249A (ja) | 2016-08-30 | 2024-09-13 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10995146B2 (enExample) |
| EP (1) | EP3506940A1 (enExample) |
| JP (3) | JP7173962B2 (enExample) |
| KR (3) | KR20190044079A (enExample) |
| CN (2) | CN118236497A (enExample) |
| AU (2) | AU2017321423C1 (enExample) |
| CA (1) | CA3034777A1 (enExample) |
| IL (1) | IL322691A (enExample) |
| MA (1) | MA46089A (enExample) |
| MX (2) | MX385598B (enExample) |
| SG (2) | SG10201913074WA (enExample) |
| WO (1) | WO2018044903A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118236497A (zh) | 2016-08-30 | 2024-06-25 | 瑞泽恩制药公司 | 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法 |
| CN110357959B (zh) * | 2018-04-10 | 2023-02-28 | 鸿运华宁（杭州）生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| AU2020210630B2 (en) * | 2019-01-23 | 2025-10-23 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| US20220288169A1 (en) * | 2019-05-24 | 2022-09-15 | The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College | Compositions and methods for the treatment and prevention of hypoglycemic complications |
| WO2021045515A1 (ko) | 2019-09-04 | 2021-03-11 | (주)에이파마 | 아이티아이에이치원의 내당능장애를 수반하는 질환의 인슐린 저항성 검출용 바이오마커로서의 용도 |
| CN113481290B (zh) * | 2021-06-30 | 2022-08-23 | 华南农业大学 | 一种klf4基因在制备检测和/或减少母鼠不良妊娠结局的产品中的应用 |
| CN114342875A (zh) * | 2022-01-12 | 2022-04-15 | 吉林大学 | 一种新型妊娠糖尿病动物模型的建立方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5836308B2 (ja) | 1977-02-10 | 1983-08-08 | 大塚製薬株式会社 | 抗体の製造方法 |
| US4206199A (en) | 1977-07-22 | 1980-06-03 | Takeda Chemical Industries, Ltd. | Novel glucagon fragment and its derivatives |
| JPS56163456A (en) | 1980-05-21 | 1981-12-16 | Otsuka Pharmaceut Co Ltd | Preparation of antigen |
| US4423034A (en) | 1980-10-16 | 1983-12-27 | Toyo Jozo Kabushiki Kaisha | Process for the preparation of antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3515112B2 (ja) | 1992-08-28 | 2004-04-05 | ノボ ノルディスク アクティーゼルスカブ | グルカゴン・レセプタ |
| JP2729159B2 (ja) | 1994-10-31 | 1998-03-18 | 日清製粉株式会社 | ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| CN1897936A (zh) | 2003-12-19 | 2007-01-17 | 默克公司 | 环状胍、含有这种化合物的组合物及其使用方法 |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ES2306165T3 (es) | 2004-06-04 | 2008-11-01 | MERCK & CO., INC. | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso. |
| DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| JP2008505905A (ja) | 2004-07-07 | 2008-02-28 | メルク エンド カムパニー インコーポレーテッド | ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法 |
| JP2008507528A (ja) | 2004-07-22 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 置換ピラゾール、このような化合物を含有する組成物及び使用方法 |
| CA2597073C (en) | 2005-02-11 | 2014-11-25 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| JP2008533200A (ja) | 2005-03-21 | 2008-08-21 | メルク エンド カムパニー インコーポレーテッド | 置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法 |
| JP2008534593A (ja) | 2005-03-30 | 2008-08-28 | メルク エンド カムパニー インコーポレーテッド | グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法 |
| AR056574A1 (es) | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
| MX2008013459A (es) | 2006-04-20 | 2008-10-30 | Amgen Inc | Composiciones de anticuerpos glucagon/compuesto de peptido 1 similar al glucagon (glp-1). |
| CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| EP2786985B1 (en) | 2007-02-09 | 2018-11-28 | Metabasis Therapeutics, Inc. | Antagonists of the glucagon receptor |
| PE20091674A1 (es) | 2008-03-27 | 2009-11-04 | Lilly Co Eli | Antagonistas del receptor de glucagon |
| WO2009140342A1 (en) | 2008-05-16 | 2009-11-19 | Schering Corporation | Glucagon receptor antagonists, compositions, and methods for their use |
| WO2010030722A1 (en) | 2008-09-15 | 2010-03-18 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8445538B2 (en) | 2008-12-19 | 2013-05-21 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds |
| WO2010088061A1 (en) | 2009-01-28 | 2010-08-05 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010093535A1 (en) | 2009-02-12 | 2010-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010098948A1 (en) | 2009-02-13 | 2010-09-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use |
| WO2010098994A1 (en) | 2009-02-25 | 2010-09-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| JP2012188352A (ja) | 2009-07-13 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩 |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| CN108410868A (zh) | 2011-09-20 | 2018-08-17 | Ionis制药公司 | Gcgr表达的反义调节 |
| JP2015505828A (ja) | 2011-12-02 | 2015-02-26 | イーライ リリー アンド カンパニー | 抗グルカゴン抗体およびその使用 |
| WO2014181229A2 (en) | 2013-05-07 | 2014-11-13 | Rinat Neuroscience Corp. | Anti-glucagon receptor antibodies and methods of use thereof |
| EP3194441A1 (en) | 2014-09-16 | 2017-07-26 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
| CN118236497A (zh) | 2016-08-30 | 2024-06-25 | 瑞泽恩制药公司 | 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法 |
-
2017
- 2017-08-29 CN CN202410379157.3A patent/CN118236497A/zh active Pending
- 2017-08-29 MX MX2019002437A patent/MX385598B/es unknown
- 2017-08-29 EP EP17762315.4A patent/EP3506940A1/en active Pending
- 2017-08-29 MA MA046089A patent/MA46089A/fr unknown
- 2017-08-29 KR KR1020197008021A patent/KR20190044079A/ko not_active Ceased
- 2017-08-29 AU AU2017321423A patent/AU2017321423C1/en active Active
- 2017-08-29 WO PCT/US2017/049137 patent/WO2018044903A1/en not_active Ceased
- 2017-08-29 US US16/328,935 patent/US10995146B2/en active Active
- 2017-08-29 CA CA3034777A patent/CA3034777A1/en active Pending
- 2017-08-29 KR KR1020237014250A patent/KR102708864B1/ko active Active
- 2017-08-29 SG SG10201913074WA patent/SG10201913074WA/en unknown
- 2017-08-29 CN CN201780065987.7A patent/CN109922831A/zh active Pending
- 2017-08-29 KR KR1020247021936A patent/KR20240110661A/ko not_active Ceased
- 2017-08-29 IL IL322691A patent/IL322691A/en unknown
- 2017-08-29 SG SG11201901355SA patent/SG11201901355SA/en unknown
- 2017-08-29 JP JP2019511610A patent/JP7173962B2/ja active Active
-
2019
- 2019-02-28 MX MX2021006457A patent/MX2021006457A/es unknown
-
2021
- 2021-04-05 US US17/222,236 patent/US11708416B2/en active Active
-
2022
- 2022-08-01 JP JP2022122568A patent/JP7633213B2/ja active Active
-
2023
- 2023-06-05 US US18/329,358 patent/US20230416384A1/en active Pending
-
2024
- 2024-09-13 JP JP2024159035A patent/JP2024178249A/ja active Pending
- 2024-12-19 AU AU2024278594A patent/AU2024278594A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528306A5 (enExample) | ||
| JP7579227B2 (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2025176106A (ja) | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 | |
| AU2021250850B2 (en) | Dosage regimen for madcam antagonists | |
| Rubbert-Roth et al. | TNF inhibitors in rheumatoid arthritis and spondyloarthritis: are they the same? | |
| JP2014533279A5 (enExample) | ||
| Fan et al. | The use of biological agents in the treatment of rheumatoid arthritis | |
| JP2019528285A5 (enExample) | ||
| JP2023528265A (ja) | Ｉｌ－２３に対する抗体及びｔｎｆアルファに対する抗体の組み合わせ療法を用いた炎症性腸疾患の治療方法 | |
| AU2017312049A1 (en) | Methods of treating Crohn's Disease with an anti-NKG2D antibody | |
| CN102307899A (zh) | 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂 | |
| JP2024069230A5 (enExample) | ||
| JP2021502065A5 (enExample) | ||
| Agarwal et al. | Review on monoclonal antibodies (Mabs) as a therapeutic approach for type 1 diabetes | |
| EP2534175A2 (en) | Treatment of a metabolic disorder | |
| CN113166238B (zh) | 使用抗体及其片段对免疫检测点抑制剂诱导的腹泻、结肠炎或小肠结肠炎的局部治疗 | |
| TW202235435A (zh) | 抗cd38抗體及其用途 | |
| JP2022548004A (ja) | オマリズマブを使用した治療方法 | |
| JP2020517648A5 (enExample) | ||
| TW202112373A (zh) | 使用抗cd38抗體之組合療法 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| RU2019107807A (ru) | Способы лечения тяжелой инсулинорезистентности путем прерывания передачи сигнала глюкагонового рецептора | |
| JPWO2022032135A5 (enExample) | ||
| RU2022112615A (ru) | Способы лечения тяжелой инсулинорезистентности путем прерывания предачи сигнала глюкагонового рецептора | |
| Funahashi et al. | FRI0166 The effectiveness of shortening intervals of infliximab and dose escalation of infliximab with rheumatoid arthritis in multi-center clinical practice |